Your browser doesn't support javascript.
HLA B53 is associated with a poor outcome in black COVID-19 patients.
Norin, Allen J; Mendoza, Rachelle; Augenbraun, Michael; Das, Ballabh.
  • Norin AJ; Department of Medicine and Cell Biology, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, United States. Electronic address: allen.norin@downstate.edu.
  • Mendoza R; Department of Pathology, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, United States.
  • Augenbraun M; Department of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, United States.
  • Das B; Department of Pathology, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, United States.
Hum Immunol ; 82(10): 713-718, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1322117
ABSTRACT
A disproportionate incidence of death has occurred in African Americans (Blacks) in the United States due to COVID-19. The reason for this disparity is likely to be multi-factorial and may involve genetic predisposition. The association of human leukocyte antigens (HLA) with severe COVID-19 was examined in a hospitalized population (89% Black, n = 36) and compared to HLA typed non-hospitalized individuals (20% Black, n = 40) who had recovered from mild disease. For additional comparison, HLA typing data was available from kidney transplant recipients and deceased donors. Hospitalized patients were followed for 45 days after admission to our medical center with death as the primary end-point. One HLA allele, B53, appeared to be more prevalent in the hospitalized COVID-19 patients (percent of positive subjects, 30.5) compared to national data in US Black populations (percent of positive subjects, 24.5). The percent B53 positive in non-hospitalized COVID-19 patients was 2.6, significantly less than the percent positive in the hospitalized COVID-19 patients (p = 0.001, Fisher's exact test) and less than the 8 percent positive listed in national data bases for US Caucasian populations. Significantly greater deaths (73 percent) were observed in HLA B53 positive hospitalized COVID-19 patients compared to hospitalized COVID-19 patients who were B53 negative (40 percent). Multi-variate analysis indicated that HLA B53 positive Black hospitalized COVID-19 patients were at a 7.4 fold greater risk of death than Black COVID-19 patients who were B53 negative. Consideration for accelerated vaccination and treatment should be given to HLA B53 positive Black COVID19 patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Genetic Predisposition to Disease / COVID-19 / HLA Antigens Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Female / Humans / Male Country/Region as subject: North America Language: English Journal: Hum Immunol Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Genetic Predisposition to Disease / COVID-19 / HLA Antigens Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Female / Humans / Male Country/Region as subject: North America Language: English Journal: Hum Immunol Year: 2021 Document Type: Article